Barreiro-Pérez Manuel, Pastor Pueyo Pablo, Raposeiras-Roubín Sergio, Montero Corominas Dolores, Uribarri Aitor, Eiros Bachiller Rocío, Rozado Castaño José, García-Cuenllas Álvarez Luisa, Serratosa Fernández Luis, Domínguez Fernando, Pascual Figal Domingo
Servicio de Cardiología, Hospital Universitario Álvaro Cunqueiro, Vigo, Pontevedra, España.
Instituto de Investigación Sanitaria Galicia Sur (IISGS), Vigo, Pontevedra, España.
Rev Esp Cardiol. 2023 Jul;76(7):555-563. doi: 10.1016/j.recesp.2023.01.010. Epub 2023 Jan 29.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has revealed several cardiovascular complications, including myocarditis caused by SARS-CoV-2 infection (COVID-19) or after messenger RNA vaccine administration. Because of the high prevalence of COVID-19, the expansion of vaccination programs, and the appearance of new information on myocarditis in these contexts, there is a need to condense the knowledge acquired since the start of the pandemic. To meet this need, this document was drafted by the Myocarditis Working Group of the Heart Failure Association of the Spanish Society of Cardiology, with the collaboration of the Spanish Agency for Medicines and Health Products (AEMPS). The document aims to address the diagnosis and treatment of cases of myocarditis associated with SARS-CoV-2 infection or messenger RNA vaccine administration.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)大流行已揭示了多种心血管并发症,包括由SARS-CoV-2感染(COVID-19)或信使核糖核酸疫苗接种后引起的心肌炎。由于COVID-19的高流行率、疫苗接种计划的扩大以及在这些情况下有关心肌炎的新信息的出现,有必要总结自大流行开始以来所获得的知识。为满足这一需求,本文件由西班牙心脏病学会心力衰竭协会心肌炎工作组起草,并得到了西班牙药品和健康产品管理局(AEMPS)的协作。该文件旨在阐述与SARS-CoV-2感染或信使核糖核酸疫苗接种相关的心肌炎病例的诊断和治疗。